Lessons learned from clinical trial queries on small biopsy collections: importance of rapid on-site evaluation
| Autor: | Jamie Voyten, Rajiv Dhir, Matthew P. Holtzman, Liron Pantanowitz, H. Scott Beasley, Sara E. Monaco, Jackie Cuda |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Adult
Image-Guided Biopsy Male medicine.medical_specialty Formative Feedback Biopsy Fine-Needle 030209 endocrinology & metabolism Site evaluation Pathology and Forensic Medicine 03 medical and health sciences 0302 clinical medicine Cytology Neoplasms Biopsy Biomarkers Tumor Medicine Humans Protocol (science) Clinical Trials as Topic medicine.diagnostic_test business.industry General surgery Tumor tissue Clinical trial 030220 oncology & carcinogenesis Biomarker (medicine) Female Biopsy Large-Core Needle business Biopsy characteristics |
| Zdroj: | Journal of the American Society of Cytopathology. 9(5) |
| ISSN: | 2213-2945 |
| Popis: | Introduction Small biopsies and cytology specimens have become increasingly important for clinical trials and biomarker testing. Thus, institutions must ensure that adequate lesional material meeting the specifications for a multitude of different protocols is available. This can be achieved using rapid on-site evaluation (ROSE). The aim of the present study was to determine the recent clinical trial biopsy characteristics and study the feedback on these collections at our institution. Materials and methods Clinical trial biopsies performed at our institution and trial feedback (including “queries”) were analyzed from the 2017 to 2019. The query data were reviewed in detail, in addition to any protocol modifications related to biopsy requirements and study protocol changes. Results A total of 698 biopsy collections were performed for clinical trial purposes for 95 trials, with most requiring biopsies at >1 time point (63.2%), for phase I or II trials (92.6%), and for specific tumor types (67.4%). Only 18 of the trials (18.9%) requiring fresh tissue biopsies provided feedback. The feedback included data from 90 cases (12.9%), of which 27 (30.0%) had queries regarding insufficient (n = 10; 37.0%) or borderline (n = 17; 63.0%) tumor tissue. Only 1 (3.7%) of these had had ROSE by cytology. ROSE was performed in accordance with institutional guidelines (45.3%), as required by the study (1.1%), or because of trial modification (5.3%). Conclusions The present investigation has shown the high volume of clinical trial biopsies managed at our academic cancer center. Feedback from the trials was low at 18.9% and frequently involved suboptimal cases without ROSE used at acquisition. This has led to more widespread adoption of ROSE to mitigate insufficient biopsy specimens and repeat procedures. The high volume of clinical trial biopsies and variability in trial needs necessitates a collaborative multidisciplinary network, including cytology services, to facilitate these important biopsies for patients with cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect